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Abstract
Background: Adverse drug events, including adverse drug reactions (ADRs), are responsible for approximately 5%
of unplanned hospital admissions: a major health concern. Women are 1.5–1.7 times more likely to develop ADRs.
The main objective was to identify sex differences in the types and number of ADRs leading to hospital admission.
Methods: ADR-related hospital admissions between 2005 and 2017 were identified from the PHARMO Database
Network using hospital discharge diagnoses. Patients aged ≥ 16 years with a drug possibly responsible for the ADR
and dispensed within 3 months before admission were included. Age-adjusted odds ratios (OR) with 95% CIs for
drug-ADR combinations for women versus men were calculated.
Results: A total of 18,469 ADR-related hospital admissions involving women (0.35% of all women admitted) and 14,
678 admissions involving men (0.35% of all men admitted) were included. Most substantial differences were seen in
ADRs due to anticoagulants and diuretics. Anticoagulants showed a lower risk of admission with persistent haematuria
(ORadj 0.31; 95%CI 0.21, 0.45) haemoptysis (ORadj 0.47, 95%CI 0.30,0.74) and subdural haemorrhage (ORadj 0.61; 95%CI
0.42,0.88) in women than in men and a higher risk of rectal bleeding in women (ORadj 1.48; 95%CI 1.04,2.11). Also,
there was a higher risk of admission in women using thiazide diuretics causing hypokalaemia (ORadj 3.03; 95%CI 1.58,
5.79) and hyponatraemia (ORadj 3.33, 95%CI 2.31, 4.81) than in men.
Conclusions: There are sex-related differences in the risk of hospital admission in specific drug-ADR combinations. The
most substantial differences were due to anticoagulants and diuretics.
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Background
Interest for sex differences in drug use and its effects is
increasing. This is partly explained by a different incidence
of several diseases in women compared with men. For ex-
ample, women are more often affected by migraine and
autoimmune diseases than men [1, 2]. Moreover, the
effectiveness of drug therapy as well as adverse drug reac-
tions differ between men and women. However, evidence
for sex differences in the incidence of adverse reactions to
drugs is still limited. Early clinical trials on drugs were
mainly performed in Caucasian young male participants
because women were excluded due to hormonal fluctua-
tions and the chance of being pregnant [3]. This also ap-
plied to preclinical trials in which the majority of animals
were male [4]. Consequently, the majority of drugs that
were marketed before the 1990s had only been studied in
male animals and men. Today, these drugs are used on a
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large scale in both women and men. Between January 1st,
1997, and December 31st in 2000, the FDA withdrew 10
drugs from the market, eight of which because they posed
a higher risk of adverse reactions in women than in men
[5]. New trials are now incorporating more diverse partici-
pants due to the introduction of the ICH guideline in
1997, which recommends to include participants who are
representative of the user population [6]. Meanwhile, in-
formation on drug safety in women is still limited espe-
cially in drugs marketed before the 1990s. Earlier research
showed that women are 1.5–1.7 times more prone to de-
velop ADRs than men [7]. Furthermore, the majority of
the studies that showed that women are more at risk for
ADRs than men are based on spontaneous reports of
ADRs that can suffer from reporting bias between women
and men [8–11]. An earlier study related the risk differ-
ence between women and men to the total number of
hospital admissions and the total number of prescriptions;
however, it was not possible to adjust for age and drug use
on patient level due to the ecological design [12].
Our main objective was to identify sex differences in
the type and number of severe ADRs that lead to hos-
pital admission. In order to examine this, we investigated
the number of ADR-associated hospital admissions over
the years for both women and men, which drugs and
ADRs caused most hospital admissions, and whether the
associated risk for the most common drug-ADR combi-
nations differed between women and men.
Methods
Data source
Data were obtained from the PHARMO Database Net-
work. The PHARMO Database Network is a population-
based network of electronic healthcare databases and
combines anonymous data from different primary and
secondary healthcare settings in the Netherlands. The
longitudinal nature of the PHARMO Database Network
system enables the follow-up of a well-defined popula-
tion in the Netherlands for an average period of 12
years. Currently, the PHARMO Database Network
covers over 6 million active persons out of 17 million in-
habitants of the Netherlands. The population within the
PHARMO Database Network comprises persons from
locations all over the Netherlands. As described by
Kuiper et al., this population corresponds in age and sex
to the demographics of the total Dutch population [13].
For this study, the Out-patient Pharmacy Database and
the Hospital Admission Database was used. The Out-
Patient Pharmacy Database comprises GP or specialist
prescribed drugs dispensed by the out-patient pharmacy.
The dispensing records include information on the type
of product, date, strength, dosage regimen, quantity,
route of administration, prescriber specialty and costs.
Drugs are coded according to the Anatomical
Therapeutic Chemical (ATC) classification [14]. The
Hospital Admission Database comprises hospital admis-
sions for more than 24 h and admissions for less than 24
h for which a bed is required (i.e. in-patient records).
The records include information on hospital admission
and discharge dates, discharge diagnoses, procedures
and treating specialism. Data from 2005 until the end of
2017 were used for this study. Diagnoses are coded with
the International Classification of Diseases 9th revision
(ICD-9) in the period 2005–2012 and according to the
ICD 10th revision from January 1st, 2013, onwards.
Study population
All hospital admissions between 1st of January 2005 up
to 31st of December 2017 that were attributed to a drug
were selected conform the ICD-9 and ICD-10 coding
system of patients with available pharmacy data [see
Additional files 1 and 2 for a detailed description and list
of EY-codes].
Only patients with at least one dispensing of the drug
that was reported as the suspected cause of the admis-
sion 3 months prior to the admission date were in-
cluded, considering that the maximum duration of a
prescription in the Netherlands is 3 months and that
changes in drug use in the preceding 3 months were re-
ported to be a predictor of hospitalizations [15].
Patients younger than 16 years old were excluded be-
cause of a low number of hospital admissions. All other
patients were categorized in the following age categories:
16–55, 56–65, 66–75, 76–85 and > 85 years old.
Outcomes
The first outcome was the number of ADR-associated
hospital admissions for both women and men over the
years. The second outcome was an overview of the drugs
and ADRs causing hospital admissions for women and
men. The final outcome was the relative risk for hospital
admissions for women and men associated with the
most common drug-ADR combinations.
Data analysis
The number of ADR-associated hospital admissions was
expressed as the percentage of the total number of hos-
pital admissions within the PHARMO Database Network
for both women and men. The most common drug
groups coded as the probable cause of an ADR and the
most common ADRs, both coded by medical coders,
were assessed by (hospital) pharmacists and the super-
vising committee. For all drug-ADR combinations with
at least 50 admissions for either women or men, age-
adjusted odds ratios (ORs) with 95% confidence limits
and p values were calculated for women versus men with
respect to the total number of female and male users
with a logistic regression model. Odds ratios were used
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as an estimate of the relative risk of a hospital admission
due to a drug. Data analyses were performed using SAS
Enterprise Guide (version 7.1) [16].
Results
In the period between 2005 and 2017, 9,575,947 hospital
admissions of patients aged 16 years and older (55.6% in
women) were registered in the PHARMO Database Net-
work. Of these admissions, 33,147 had an ICD code re-
lating the admission to a drug (0.35 % of all hospital
admissions). Within the ADR-related hospital admis-
sions, 18,469 admissions concerned women (0.35 % of
all hospital admissions in women and 55.7% of all ADR-
associated admissions) and 14,678 admissions concerned
men (0.35 % of all hospital admissions in men and 44.3%
of all ADR-associated admissions). Women had a mean
age of 72.1 years at admission which was statistically sig-
nificantly higher than men who had a mean age of 71.3
years in ADR-related hospital admissions (Table 1).
There was no difference between women and men in
the proportions of ADR-related hospitalizations (Fig. 1).
The number of ADR-associated hospital admissions in-
creased over time, except for a lower number in 2012.
The ADR-related hospital admissions were caused by
80 different drug groups and included 2213 different
ADRs. The 10 drug groups with the highest number of
ADR-related admissions are presented in Fig. 2. The
percentage of ADR-related hospital admissions with re-
spect to the number of female and male users are shown
in Fig. 3. The 10 most frequent ADRs that were respon-
sible for the admissions are shown in Table 2.
There were 7797 unique drug-ADR combinations, 39
combinations had at least 50 hospital admissions in ei-
ther women or men. In total, 9 drug groups were associ-
ated with 36 different adverse drug reactions. Figure 4
shows the age-adjusted ORs with corresponding p values
of the drug-ADR combinations for women versus men.
In 9 combinations, women were more at risk and in 6
combinations men were more at risk. Detailed results
are shown in Additional file 3.
The most distinct differences in risk between women
and men, as shown in Fig. 4, were seen in ADR-related
hospitalizations due to anticoagulants. Anticoagulants
were associated with a lower risk of a hospital admission
with unspecified haematuria (ORadj 0.16; 95% CI 0.09,
0.34), recurrent and persistent haematuria (ORadj 0.31;
95% CI 0.21, 0.45), haemoptysis (ORadj 0.47, 95% CI
0.30, 0.74), subdural haemorrhage (ORadj 0.61; 95% CI
0.42, 0.88) in women and a higher risk of haemorrhage
of anus and rectum (ORadj 1.48; 95% CI 1.04, 2.11) and
haemorrhage, not elsewhere classified (ORadj 1.38; 95%
CI 1.18, 1.62) in women.
Another drug group that showed large differences
were diuretics which were associated with a higher risk
of hospital admission due to hypokalaemia for women
when using thiazides (ORadj 3.03; 95% CI 1.58, 5.79)
and other diuretics (ORadj 2.05 95% CI 1.23, 3.42). Fur-
thermore, women had an increased risk of admission
due to hyponatraemia with thiazide use (ORadj 3.33,
95% CI 2.31, 4.81) and other diuretics (ORadj 2.21, 95%
CI 1.63, 3.00). Thiazide diuretics also showed an in-
creased risk of a hospital admission due to urinary tract
infections (ORadj 2.26; 95% CI 1.21, 4.23) for women
compared with men.
Antihypertensive drugs including drugs acting on the
renin-angiotensin system showed a lower risk in women
for hospital admissions due to syncope and collapse
(ORadj 0.51; 0.35, 0.75) than in men. Antineoplastic
drugs used by women resulted in a higher risk for hos-
pital admissions due to malaise and fatigue (ORadj 1.50;
95% CI 1.05, 2.14) and due to nausea and vomiting
(ORadj 1.56; 95% CI 1.17, 2.08). Hypoglycaemia as an
ADR caused by drugs used in diabetes showed a statisti-
cally significantly lower risk in women (ORadj 0.63; 95%
CI 0.43, 0.91) than in men.
Discussion
Our study showed that 0.35% of all hospital admissions
were coded as an ADR-related admission. There was no
difference in the proportion of ADR-related hospital ad-
missions between women and men.
There was a difference in risk for specific drug-ADR
combinations; women were more at risk in 9 and men in
6 combinations. The most distinct differences were seen
in ADRs due to anticoagulants and diuretics.
The 0.35% of ADR-related hospital admissions we
found was much lower than the 5% mentioned in the lit-
erature [17]. Poor recognition and registration of ADRs
as the cause of admission could explain this discrepancy.
In addition, most of the studies into ADR-related hos-
pital admissions consist of actively reported or actively
registered ADRs at the time of admission resulting in a
higher chance of recognition than in retrospective data
[8, 9, 17–22]. We studied hospital admissions that are
coded after discharge; therefore, our results are also in-
fluenced by the method and accuracy of coding by the
Table 1 Age distribution of women and men with ADR-
associated hospital admissions between the 1st of January 2005
up to the 31st of December 2017
Women (18,469) Men (14,678)
Mean age, years (SD) 72.1 (15.5) 71.3 (13.1)
Age categories, years, n (%) 16–55 2666 (14.4) 1650 (11.2)
56–65 2460 (13.3) 2459 (16.8)
66–75 3886 (21.0) 4183 (28.5)
76–85 6070 (32.9) 4823 (32.9)
> 85 3387 (18.3) 1563 (10.6)
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hospitals. This problem has been described before [22].
Although this probably leads to underreporting, it will
not influence differences in risk between women and
men. The frequency of ADR-related hospital admissions
increased over time for both women and men. This
could be explained by changes in the methods of coding
over time and the switch from the ICD-9 to ICD-10 cod-
ing system causing the low frequency in 2012. Further-
more, there has been more attention for ADRs as a
cause of admission and for coding over the last few years
as a measure of healthcare quality [23]. In addition, there
was a difference in the number of participating hospitals
over time and that might influence the increase in the
number of ADR-related admissions due to differences in
coding between hospitals. However, this will not influ-
ence differences between women and men.
Literature suggests that women tend to have a 1.5–1.7
times higher risk of developing ADRs [7]. Also, women
report more ADRs than men; therefore, research into
sex differences in ADRs is possibly subject to reporting
bias caused by gender differences [8–11]. In contrast, we
showed that there was no difference between women
and men in the proportion of severe ADRs that were as-
sociated with hospital admissions.
Anticoagulants can cause, as a result of the mechanism
of intended action, different types of haemorrhages.
Rodenburg et al. showed that the risk of a hospital ad-
mission differs between women and men and for differ-
ent types of bleeding [12]. We show similar results. In
our study, men were more at risk for admission caused
by unspecified, and recurrent and persistent haematuria,
haemoptysis and subdural haemorrhage. The higher risk
Fig. 1 The percentage of ADR-related hospital admissions of the total number of hospital admissions. In total, there were 5,323,990 women and
4,251,957 men admitted
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Fig. 2 The number of ADR-related hospital admissions of women and men per drug group. These groups are the ten most frequently
responsible drug groups causing hospital admissions
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of haematuria might be explained by the development of
prostate cancer [24]. Haemoptysis is a known complica-
tion of lung cancer which is more common in men and
might explain the difference [25]. However, the inci-
dence in women is increasing relative to the incidence in
men [26]. If the haemoptysis admissions are due to lung
cancer, the difference in risk will diminish over time.
The risk of unspecified haemorrhage and haemorrhage
of the anus and rectum was higher in women. Rectal
bleeding is a known symptom of colorectal cancer. Inter-
estingly, men more often have left-sided colorectal cancer
which presents with rectal bleeding whereas women more
often have right-sided colorectal cancer with symptoms
such as anaemia and weight loss [27, 28]. Therefore, the
higher risk of rectal bleeding in women is not explained
by colorectal cancer. We did not find the difference in
gastrointestinal haemorrhage that Rodenburg et al. found
after adjustment for the number of prescriptions [12].
This might be the result of the introduction of the medical
pharmaceutical decision rule on gastric protection for
non-steroidal anti-inflammatory drugs, developed by the
Royal Dutch Pharmacists Association and Health Base in
2013 [29]. Women might more often receive gastric
protection for the prevention of gastric complications, as
recommended by the Dutch guideline [30], due to more
frequent use of interacting drugs such as selective sero-
tonin reuptake inhibitors (SSRIs).
An increased risk of women to be admitted due to elec-
trolyte disturbances, hyponatraemia and hypokalaemia,
when using diuretics was another result Rodenburg et al.
found [12]. We showed similar results in both thiazides and
other diuretics. Women might be more at risk of hypona-
traemia because sex hormones influence the regulation of
arginine vasopressin (AVP) resulting in a higher renal so-
dium excretion in women as shown in a study on sex differ-
ences in the regulation of AVP during hypotonic saline
infusion [31]. They suggested that testosterone has a greater
influence on the renal sodium excretion than oestrogen be-
cause the excretion did not differ between phases of the
menstrual cycle. The potentially higher risk of hyponatre-
mia in general along with the use of thiazide diuretics,
which are known to cause electrolyte disturbances because
of their mechanism of action [32], might explain the higher
risk in women compared with men. Another result we
found was a higher risk in women to develop urinary tract
infections (UTIs) when using thiazide diuretics. Diuretics
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Fig. 3 The percentage of ADR-related hospital admissions in women and men. The percentage is relative to the number of female and
male users
Table 2 The 10 most frequent ADRs responsible for hospital admissions for women and men
Adverse drug reaction Total admissions (n) Women (n) Women (% of total female
admissions)
Men (n) Men (% of total male
admissions)
Constipation 788 471 0.009 317 0.007
Hypo-osmolality and hyponatraemia 751 597 0.011 154 0.004
Haemorrhage, not elsewhere classified 650 365 0.007 285 0.007
Urinary tract infection, site not specified 625 422 0.008 203 0.005
Gastrointestinal haemorrhage, unspecified 606 290 0.005 316 0.007
Nausea and vomiting 575 392 0.007 183 0.004
Syncope and collapse 572 297 0.006 275 0.006
Pneumonia, unspecified 504 238 0.004 266 0.006
Drug-induced fever 492 264 0.005 228 0.005
Heart failure, unspecified 434 233 0.004 201 0.005
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have been described to cause lower urinary tract symptoms
before but the underlying mechanism is still unknown [33].
However, the difference in risk we found between women
and men might be explained by the higher incidence of
UTIs in women compared with men [34]. It is possible that
women are more frequently tested for UTIs than men
when admitted with unexplained symptoms such as incon-
tinence, nocturnal voiding, confusion and malaise and elder
women have a higher risk of asymptomatic bacteriuria than
men [35]. Also, the admissions could be the result of dehy-
dration due to the urinary tract infection and concomitant
use of thiazides.
A higher risk for men than women of hospital admis-
sions due to syncope and collapse when using antihyper-
tensive drugs and drugs acting on the renin-angiotensin
system was also found by Rodenburg et al. [12]. We
found this association within a larger drug group due to
differences in coding between ICD-9 and ICD-10 and
therefore included ATC code C09 (drugs acting on the
renin-angiotensin system) in addition to ATC code C02
(antihypertensive drugs). Sex differences in the renin-
angiotensin system have been described, but show con-
trasting results. It has been suggested that angiotensin-
converting enzyme (ACE) inhibitors have a larger effect
on the reduction of blood pressure in male rats and male
rats have a higher ACE2 activity [36]. A recent study
suggested that women with heart failure (HF) reach the
same treatment effects (i.e. relative risk of mortality or
hospital admission for HF) with lower doses of RAAS
blockers than men, and do not benefit from up-titrating
to guideline-recommended doses [37]. This means that
the underlying pathophysiology of HF may interfere with
treatment effects in a sex-specific manner. Further re-
search could give more insight into which drugs are re-
sponsible for this reaction and if the indication for
treatment is an additional risk factor.
Antineoplastic drugs posed a higher risk in women for
malaise, fatigue, nausea and vomiting. All these ADRs are
mentioned in the literature to occur more frequently in
women [8]. We now confirmed that not only in spontan-
eous reporting systems there is a higher risk for women
but also in the systematic recorded cases we studied.
Rodenburg et al. showed that men have a higher risk
to be admitted due to drugs used in diabetes causing
hypoglycaemia resulting into coma [12]. We saw a
higher risk for men for hypoglycaemia without coma but
not in admission for hypoglycaemia with coma.
The sex differences in ADR-related hospital admis-
sions described above can be due to several differences
between women and men in pharmacokinetics (PK) and
pharmacodynamics (PD) [38–41]. However, more re-
search is needed to determine whether the underlying
mechanisms can be explained by PK and/or PD
differences.
One of the strengths of our study was the
minimization of reporting bias by investigating only
Fig. 4 In total, 18,469 women (n) and 14,678 men (n) had an ADR-associated admission. This was 0.35% of the total number of admitted women
(N = 5,323,990) and 0.35% of the total number of admitted men (N = 4,251,957). This figure shows the age-adjusted odds ratios (ORadj) for
women versus men for drug-ADR combinations. All combinations with at least 50 admissions in either women or men are presented. ORs with a
p value < 0.05 are statistically significant and labelled with the corresponding ADR [see Additional file 3 for all values]
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ADR–related hospitalizations. These ADRs are so severe
that it was expected that women and men are equally
admitted to a hospital. This could explain why we do
not see a difference in the number of ADR-related hos-
pital admissions with respect to the total number of ad-
missions for women and men. Another strength of this
study was the availability of individual patient informa-
tion, which enables to adjust for age.
A limitation of this study was that the total number of
users is not the total number of patients at risk. This is
due to changes in data coverage. The hospitals that con-
tribute are different over the years. Whereas the pharmacy
data is available from a specific number and region. It is
possible that pharmacy data of the patient was available;
however, the patient was admitted to a hospital that was
not included. This might influence the number of admis-
sions; however, this will not result in differences between
women and men. Another limitation was the unavailabil-
ity of inpatient use of antineoplastic drugs. Antineoplastic
drugs show, relative to the number of users, the highest
number of ADR-related hospital admissions. However,
this was only adjusted for the number of antineoplastic
drugs that are used in the outpatient setting. Parenteral
administrations or other administrations of antineoplastic
drugs in the hospital are not registered in the Outpatient
Pharmacy database. This will not have an effect on the dif-
ference between women and men but can influence the
proportion of ADR-related hospital admissions compared
with other drug groups. Several cardiovascular drugs were
coded differently in ICD-9 and ICD-10 and therefore
combined into one large group including ATC codes
C01B (antiarrhythmic drugs), C07AA, C07AB, C07B,
C07C (beta-blocking agents and combinations) and C08
(calcium channel blockers). There could be differences in
risk for each of the subgroups; however, we are not able to
identify it by the method of coding. Another limitation
was that we were not able to adjust for co-morbidities.
We did compare the chronic disease scores for all patients
with an ADR-associated hospital admission. Women had
a slightly lower mean chronic disease score than men,
which should be taken into account in future research.
Furthermore, we were not able to adjust for potential
differences in drug dose and weight that can differ
between women and men. Although we are unaware
of sex-specific dosing guidelines in the Netherlands,
except for drugs dosed on body weight or body sur-
face area resulting in a more sex-specific dose, ADRs
cannot only be explained by sex differences in weight
[42]. Also, we were not able to measure the adher-
ence to the treatment that might differ between
women and men. Several studies on sex and gender
differences in adherence show that women are less
adherent than men [43–45], although no differences
were seen in antihypertensive drug users [46].
Perspectives and significance
We show that there was no difference in the proportion
of ADR-related hospital admissions between women and
men. However, there were differences in the risk of hos-
pital admission in specific drug-ADR combinations. The
most substantial differences were seen in ADRs due to
anticoagulants and diuretics. Further research is needed
to adjust for potential confounding factors that might
have influenced the results, for example drug dose, other
drugs in use and comorbidities. In addition, research
into PK and PD is necessary to investigate whether these
sex differences in ADRs are predicted by PK or PD. This
would provide information for personalized medicine in
the future.
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